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SUMMARY
Two genetic diseases, Gorlin syndrome and McCune-Albright syndrome (MAS), show completely opposite symptoms in terms of bone
mineral density and hedgehog (Hh) activity. In this study, we utilized human induced pluripotent stem cell (iPSC)-based models of the
two diseases to understand the roles of Hh signaling in osteogenesis. Gorlin syndrome-derived iPSCs showed increased osteoblastogen-
esis andmineralizationwithHh signaling activation and upregulation of a set of transcription factors in an osteogenic culture, compared
with the isogenic control. MAS-specific iPSCs showed poor mineralization with low Hh signaling activity in the osteogenic culture;
impaired osteoblastogenesis was restored to the normal level by treatment with an Hh signaling-activating small molecule. These data
suggest that Hh signaling is a key controller for differentiation of osteoblasts from precursors. This study may pave a path to new drug
therapies for genetic abnormalities in calcification caused by dysregulation of Hh signaling.
INTRODUCTION
Hedgehog (Hh) signaling is a highly conserved pathway be-
tween species, acting as a mitogen and morphogen in
various developmental processes (Ingham and McMahon,
2001). Mouse genetics studies have highlighted the
requirement of Hh signaling to specify skeletal progenitors
into osteoblast precursors expressing runt-related tran-
scription factor (TF) 2 (Runx2), a master TF for osteoblast
development (Komori et al., 1997; Long et al., 2004).
Both Gli activators and repressors affect the Hh function
in this context (Joeng and Long, 2009). In adult mice,
constitutive activation of Hh signaling by Patched1
(Ptch1) haploinsufficiency led to high bone mass with an
acceleration of both bone formation and bone resorption
(Ohba et al., 2008).
Dysregulation of Hh signaling has been implicated in
human diseases (Mullor et al., 2002). Mutations of
PTCH1, which encodes a receptor of Hh, are known to
cause Gorlin syndrome (OMIM 109400), a rare auto-
somal-dominant disorder characterized by multiple tumor
formation and skeletal anomalies (Gorlin, 1995; Gorlin
and Goltz, 1960). Most individuals with this disease
have skeletal anomalies, and ectopic calcification particu-
larly in the cerebral falx is present in more than 90% of
the affected individuals. Heterozygous Ptch1-deficient
(Ptch1+/) mice have features that recapitulate those of pa-
tients with Gorlin syndrome (Goodrich et al., 1997). They
have higher bone mineral density than age-matched con-
trols (Ohba et al., 2008).
Molecular mechanisms underlying the maintenance of
human bone mass have attracted much attention due to
their fundamental importance for the understanding of
bone pathology. From this point of view, it is noteworthy
that two different Hh-related syndromes, Gorlin syndrome
and McCune-Albright syndrome (MAS) (OMIM 174800),
are characterized by completely opposite features of osteo-
blast differentiation. Gorlin syndrome exhibits activation
of Hh signaling and enhancement of mineralization, while
MAS is often accompanied with fibrous dysplasia (FD) of
immature bones with poor mineralization (Albright et al.,
1937; Weinstein et al., 1991). FD is a genetic, non-inherit-
able rare bone disease caused by a postzygotic mosaic acti-
vation mutation (R201H or R201C) of the a-subunit of
stimulatory G protein (Gas) encoded by GNAS, and this
mutation is also observed in MAS (Albright et al., 1937;
Lichtenstein, 1938; Turan and Bastepe, 2015). FD often
leads to wheelchair life due to bone deformation, fractures,
and severe pain. Khan et al. (2018) elegantly described that
a Gnas (R201H) knockin mouse line showed reduced
mineralization in the mutant bones, and the increased
osteoid surface demonstrated poor osteoblastogenesis
with suppressed Hh signaling and enhanced Wnt
signaling.
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Despite the opposite status ofHh signaling and osteogen-
esis in the twoHh-related genetic diseases, few studies have
focused on differences in the mechanisms of bone forma-
tion, particularly the mechanisms involving osteoblast dif-
ferentiation, between the diseases. In addition, although
human cell models of these diseases would help elucidate
their pathogenesis at the cellular and molecular levels
and help develop therapeutic strategies, such models
remain to be established.
We previously generated induced pluripotent stem cells
(iPSCs) derived from patients with Gorlin syndrome (Gor-
lin iPSCs), who therefore carried heterozygous loss-of-func-
tion mutations in PTCH1; Gorlin iPSCs showed hypersen-
sitivity to Hh signaling, and Hh signaling may be
associated with accelerated osteoblast differentiation (Ha-
segawa et al., 2017). Gorlin iPSCs also demonstrated
enhanced Hh signaling, which in turn suppressed Wnt
and BMP signaling (Hasegawa et al., 2017). However,
once cultured in a conventional osteogenic differentiation
medium, they suddenly acquired steep upregulation of
Wnts and BMPs to promote osteoblastogenesis. Therefore,
it was necessary to investigate the process of osteoblast dif-
ferentiation of Gorlin iPSCs in defined culture systems, to
examine the direct effect of Hh activation on human oste-
oblast differentiation. In addition, we generated MAS-spe-
cific iPSCs (MAS iPSCs) by introducing GNAS gene muta-
tion with genome-editing techniques. MAS iPSCs had
constitutively activatedGNAS, which increased the cellular
cAMP level under an unstimulated condition (T.A., S.O.,
K.W., A.S., T.S. and T.N., unpublished data). We reasoned
that we would achieve a better understanding of the corre-
lation between intracellular Hh signaling activity and oste-
ogenic capacities by utilizing the two disease-specific iPSC
lines.
In this study, we sought to gain insight into the involve-
ment of Hh signaling in human osteoblastogenesis by tak-
ing advantage of the two platforms that we developed:
the osteoblast induction protocol for human iPSCs, in
which small-molecule-mediated activation of Hh signaling
contributed to differentiation of human iPSCs (Kanke et al.,
2014; Zujur et al., 2017), and the human iPSC-based disease
models, Gorlin iPSCs andMAS iPSCs. This study provides a
valuable foundation for establishing stem cell-based sys-
tems to delineate the mechanism of skeletal abnormalities
underlying human genetic disorders. In addition, our re-
sults suggest the possibility of drug therapies for FD.
RESULTS
Osteogenic Capacities of Gorlin iPSCs in an Osteoblast
Induction Culture
We previously established two iPSC lines from different pa-
tients with Gorlin syndrome (Gorlin iPSCs; see Experi-
mental Procedures) (Hasegawa et al., 2017).We used Sanger
sequencing to confirm that the PTCH1-loci mutations in
each of the two Gorlin iPSC lines were the same as those
identified in the tissues of the patients of origin (Fig-
ure S1A). Two other hiPSC lines that were not relevant to
Gorlin syndrome were also prepared as controls (wild-
type [WT] iPSCs; see Experimental Procedures). All four
iPSC lines were adapted to a feeder-free condition in Essen-
tial 8 medium (see Experimental Procedures). We
confirmed that themorphology of theGorlin iPSC colonies
was similar to that of the WT iPSC colonies under the con-
ditions used; both the WT and Gorlin cells demonstrated
tightly packed colonies of small cells with defined borders
and the high nucleoplasmic ratio (Figure 1A). Both the
WT and Gorlin iPSCs expressed markers of pluripotency,
including NANOG and SSEA4 (Figure S1B).
To elucidate the impact of Gorlin syndrome-associated
PTCH1 mutations on human osteoblastogenesis, we
Figure 1. Osteogenic Capacities of Gorlin iPSCs in the Osteoblast Induction Culture
(A) The morphology of colonies of WT and Gorlin iPSCs adapted to Essential 8 medium. Data of two lines (1 and 2) are shown for each type of
iPSC. Scale bar, 100 mm.
(B) A schematic of the protocol of the osteoblast induction culture.
(C) Calcification in the osteoblast induction culture of WT and Gorlin iPSCs with or without SAG treatment. von Kossa staining was per-
formed at days 0, 10, and 17 of the culture. Mineral deposition was detected as black staining. Data of two lines (1 and 2) are shown for
each type of iPSC.
(D) Quantification of RUNX2-positive cells in the osteoblast induction culture of WT and mutant (MT) iPSCs by flow cytometry (FCM). The
cells were cultured under a condition with or without SAG as indicated. FCM analysis was performed for RUNX2 at days 0 and 17 of the
culture. Blue dotted lines show signal intensities from staining with the immunoglobulin G (IgG) isotype control. Light blue lines show
signal intensities from the staining with an anti-RUNX2 antibody. The positive gate was set to the area where the isotype control was
present at around 8%. The FCM analyses were performed in two or three independent experiments using two lines (1 and 2) for each type of
iPSC; a representative histogram is shown.
(E) The mRNA expression of osteoblast marker genes in the osteoblast induction culture of WT and MT iPSCs without SAG. qRT-PCR analysis
was performed at the indicated days of the cultures. Data are the means ± SD from three independent experiments using two lines (1 and 2)
for each type of iPSC. *p < 0.05 versus WT2 iPSCs at the indicated day of the culture. **p < 0.05 versus both WT1 and WT2 iPSCs at the
indicated day of the culture.
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Figure 2. Expression of GLI in the Gorlin iPSC-Derived Osteogenic Population
(A) The mRNA expression of GLI1 in the osteoblast induction culture of WT and MT iPSCs without SAG. qRT-PCR analysis was performed at
day 17 of the culture. Data are the means ± SD from three independent experiments using two lines (1 and 2) for each type of iPSC. *p <
0.05 versus WT1 iPSCs. **p < 0.05 versus both WT1 and WT2 iPSCs. The normalized expressions are shown relative to those of calibrator
samples (WT1 iPSCs on day 17).
(B) Protein expression of endogenous GLI3 in the osteoblast induction culture of WT1 and Gorlin-1 iPSCs. The GLI3 expression was
analyzed by immunoblotting using specific antibodies at day 17 of the culture. Band intensities were quantified by normalization to those
(legend continued on next page)
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cultured Gorlin and WT iPSCs according to our stepwise
osteoblast differentiation protocol, in which 3-day meso-
derm induction is followed by 14-day osteoblast induction
(Kanke et al., 2014) (Figure 1B). In that protocol, the osteo-
genicmolecule TH (Ohba et al., 2007) and the Smoothened
agonist (SAG), which was an Hh signaling activator, are
used in the osteoblast induction phase; we confirmed
that the protocol achieved the activation of Hh signaling
and upregulation of osteoblast marker genes in WT iPSCs
by the 17th day of culture (Figure S2). These results suggest
that the osteoblast induction is at least partly linked with
Hh signaling activation in the protocol.
Both WT iPSCs and Gorlin iPSCs showed decreased
expression of the pluripotency marker POU5F1 and
increased expression of the mesoderm marker MIXL1 at
the end of themesoderm induction stage (day 3) compared
with those at day 0; there was no clear difference in the
expression of these genes between the genotypes (Figures
S3A and S3B). To induce osteoblast differentiation of the
WT iPSC- or Gorlin iPSC-derived mesodermal cells, we
then treated them with TH in the presence or absence of
SAG for another 2 weeks (Figure 1B). von Kossa staining
at day 17 of the culture revealed that Gorlin iPSCs showed
increased calcification compared with WT iPSCs even in
the absence of SAG (Figure 1C; compare the right four
rows). WT iPSCs with SAG treatment showed increases in
calcification compared with those without SAG treatment
(Figure 1C; compare the left two rows and Figure S3C). In
addition, Gorlin iPSCs with SAG treatment showed in-
creases in calcification compared with those without SAG
treatment (Figure S3D). These data suggest that Hh
signaling activation could enhance the calcification of os-
teoblasts derived from iPSCs.
To examine whether the increased calcification is related
to the enhancement of osteoblast differentiation, we
checked the expression of osteoblastic markers in the cul-
ture of each iPSC line. Since Hh input is required for the
specification of progenitors into Runx2-positive osteoblast
precursors (Long et al., 2004; St-Jacques et al., 1999), we
analyzed RUNX2-positive cells by flow cytometry at day
17 of the culture. As shown in Figure 1D, Gorlin iPSC cul-
tures showed a higher percentage of RUNX2-positive cells
than WT iPSC cultures in the absence of SAG (Figure 1D).
In addition, qRT-PCR analysis demonstrated that the
expression level of COL1A1, an early marker of osteoblast
differentiation, and the expression levels of SP7 and
BGLAP, mid- to late osteoblast markers, were significantly
higher inGorlin iPSCs than inWT iPSCswith no SAG treat-
ment (Figure 1E). However, the difference was noticeable at
day 10 and became less at day 17. This may represent accel-
erated differentiation of Gorlin iPSCs at the earlier phase of
the culture, and WT iPSCs may reach the similar level to
Gorlin iPSCs at the later phase. In addition, Gorlin iPSCs
were unlikely to further differentiate or maturate at the
later phase. Thus, the increased calcification of Gorlin
iPSCs in the osteoblast induction culture was accompanied
with higher expressions of osteoblast markers, supporting
augmentation of the osteogenic capacity in Gorlin iPSCs
even without exogenous activation of Hh signaling; Gorlin
syndrome-associated PTCH1 mutations are likely to have
positive impacts onhumanosteoblastogenesis. The pheno-
types of Gorlin iPSCs support our previous findings that pa-
tients with Gorlin syndrome and Ptch1+/ mice exhibited
increases in bone mass with accelerated bone formation
(Goodrich et al., 1997; Ohba et al., 2008).
Changes of GLI TFs in Gorlin iPSCs upon the
Osteoblast Induction
Since previous findings showed ectopic activation of Hh
signaling in Ptch1+/ mice (Goodrich et al., 1997), we next
explored whether downstream mediators of the signaling
were affected inGorlin iPSCs upon the osteoblast induction.
The mRNA expression of GLI1, a readout of Hh signaling as
well as a transcriptional activator acting downstream of the
signaling (Ingham and McMahon, 2001), was significantly
upregulated in Gorlin iPSCs compared with WT iPSCs in
the osteoblast induction culture (Figure 2A). This result sug-
gests that the Gorlin syndrome-associated PTCH1mutation
leads to constitutive activation ofHh signaling inhumanos-
teoblastogenesis. This is consistentwith the previous notion
that heterozygous germline loss-of-function mutations of
PTCH1 release PTCH1-mediated SMO suppression and
thereby activate Hh signaling (Alman, 2015; Briscoe and
Thérond, 2013; Fujii and Miyashita, 2014).
of b-actin in each group. GLI3FL and GLI3rep indicate their relative intensity levels to WT1; GLI3rep/GLI3FL indicates the ratio of intensity
levels of GLI3rep to those of GLI3FL in each group.
(C) The mRNA expression of GLI1 in the osteoblast induction culture of WT1 and Gorlin-1 iPSCs with or without cyclopamine (Cyc). qRT-PCR
analysis was performed at day 17 of the culture. Data are the means ± SD from three independent experiments. *p < 0.05. The normalized
expressions are shown relative to those of WT1 iPSCs on day 17.
(D) Calcification in the osteoblast induction culture of WT1 and Gorlin-1 iPSCs with or without cyclopamine (Cyc). von Kossa staining was
performed at day 17 of the culture.
(E) Quantification of RUNX2-positive cells in the osteoblast induction culture of WT1 and Gorlin-1 iPSCs without SAG, in the presence or
absence Cyc. FCM analysis was performed for RUNX2 at day 17 of the culture. Blue dotted lines show signal intensities from the staining
with the IgG isotype control. Light blue and green lines show signal intensities from the staining with an anti-RUNX2 antibody.
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Hh signaling has also been demonstrated to regulate the
expression of GLI3 as well as GLI1; the signaling suppresses
processing of Gli3 into its truncated form in mouse limb
bud cells (Wang et al., 2000), and mouse genetics and
biochemical studies support the idea that Gli3 exerts
repressive actions on osteoblast differentiation (Ohba
et al., 2008). Based on these reports, we investigated the
protein expression of GLI3 in WT and Gorlin iPSCs. The
truncated repressor form of GLI3 (GLI3rep) was detected
in both WT and Gorlin iPSCs at a similar level (Figure 2B).
Although the full-length formofGLI3 (GLI3FL)was themi-
nor form in both WT and Gorlin iPSCs, the amount of
GLI3FL was much increased in Gorlin iPSCs (Figure 2B).
As a result, the ratio of GLI3rep to GLI3FL was decreased
in Gorlin iPSCs compared with WT iPSCs. These data sug-
gest that GLI3 processing is suppressed by the Gorlin syn-
drome-associated PTCH1 mutation in human osteoblasto-
genesis, probably due to the activation of Hh signaling
demonstrated by GLI1 upregulation (Figure 2A).
To clarify the involvement of Hh signaling activation in
the augmented osteogenic capacity of Gorlin iPSCs, we
investigated the effect of Hh inhibition on osteoblast dif-
ferentiation by cyclopamine, an Smo antagonist that sup-
presses the Hh signaling activity. Treatment with cyclop-
amine resulted in neither an increase in GLI1 expression
nor an enhancement of calcification in Gorlin iPSCs at
day 17 of the osteoblast induction culture (Figures 2C
and 2D). Treatment with cyclopamine alone did not cause
any change inGLI1 expression or calcification inWT iPSCs
at day 17 (Figures 2C and 2D). We also examined the per-
centage of RUNX2-positive cells in WT and Gorlin iPSCs
with or without the cyclopamine treatment. Consistent
with the above results, cyclopamine treatment reduced
the ratio of Runx2-positive cells only in Gorlin iPSCs
(from 55.9% to 39.1%) (Figure 2E). Thus, these data suggest
that Hh signaling activation plays an important role in the
enhancement of osteoblastogenesis and mineralization in
Gorlin iPSCs.
Expression Profiling of Gorlin iPSCs in the Osteoblast
Induction Culture
To examine which signaling pathways and genetic net-
works were affected by Gorlin syndrome-associated
PTCH1 mutation in human osteoblastogenesis, we per-
formed RNA sequencing (RNA-seq) analysis in the osteo-
blast induction culture (without SAG treatment) of WT
and Gorlin iPSCs (Gorlin 1). The triplicate samples of
each genotype were clustered in the same group (Fig-
ure S4A), and the average expression values of the triplicate
were used for further analysis. We identified 753 genes that
were differentially expressed between the Gorlin iPSC- and
WT iPSC-derived osteoblastic populations at day 17 of the
culture, according to the criteria shown in Figure S4B; 559
genes were upregulated and 194 genes were downregulated
in Gorlin iPSCs compared with WT iPSCs (Figures 3A and
3B; Table S1). Genes related to osteoblast differentiation
and calcification, such as ASPN, BMP7, RSPO2, and DKK1,
were included as the differentially expressed genes (Fig-
ure 3B). A pathway enrichment analysis using DAVID iden-
tified multiple gene ontology (GO) categories that were
significantly enriched in the differentially expressed genes
(Table S2). It is notable that the enriched GO terms derived
from the 193 downregulated genes were related to the cell
cycle, including nuclear division (GO:0000280), mitosis
(GO:0007067), and the M phase of the mitotic cell cycle
(GO:00000087). This result may reflect acceleration of
Figure 3. Transcriptome Analyses in the Gorlin iPSC-Derived Osteogenic Population
(A) The volcano plot of gene expression between WT1 and Golrin-1 cells differentiated from iPSCs in RNA-seq analysis. Statistical sig-
nificance genes that were calculated by Cuffdiff with red dots. Dark blue line and light blue line were the criteria indicated in Figure S4B.
(B) Scatterplot indicating the ratio of gene expressions between WT1 and Gorlin-1 cells differentiated from iPSCs in RNA-seq analysis.
Upregulated genes and downregulated genes that were passed through the criteria indicated in Figure S4B are highlighted with light blue
dots and dark blue dots, respectively.
(C) Fold change expression of transcription factors in WT1 and Gorlin-1 cells identified as the differentially expressed genes. Fold change
expressions of Gorlin-1 cells compared with WT1 cells are shown in log2 ratio.
(D) A list of transcription factors that were upregulated in Gorlin-1 iPSCs compared with WT1 iPSCs and related with bones, mineralization,
and osteoblast differentiation in GO analysis.
(E) The mRNA expression of CDX1, FOXO1, FOXD1, and ID4 in the osteoblast induction culture of WT1, WT2, Gorlin-1, and Gorlin-2 iPSCs.
qRT-PCR analysis was performed at day 17 of the culture. Data are the means ± SD from three independent experiments. *p < 0.05 versus
WT1 iPSCs. **p < 0.05 versus both WT1 and WT2 iPSCs.
(F) Calcification in the osteoblast induction culture of WT1 and Gorlin-1 iPSCs with or without GANT61. von Kossa staining was performed
at day 17 of the culture.
(G) The mRNA expression of GLI1, CDX1, FOXO1, FOXD1, and ID4 in the osteoblast induction culture of WT1 and Gorlin-1 iPSCs with or
without GANT61. qRT-PCR analysis was performed at day 17 of the culture. Data are the means ± SD from three independent experiments.
When ANOVA indicated differences among the groups, multiple comparisons among each experimental group were performed using Da-
nette t test. Statistical significance was defined at *p < 0.05. Only GLI1 mRNA, the normalized expressions are shown relative to those of
WT1 iPSCs on day 17.
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differentiation rather than proliferation in Gorlin iPSCs
under the induction culture.
We next attempted to gain insight into transcriptional
networks underlying the positive impacts of PTCH1 muta-
tion on human osteogenesis. We analyzed differentially
expressed TFs between Gorlin and WT iPSCs using
PANTHER, a web-based enrichment analysis, and found
14 upregulated and 3 downregulated TFs in Gorlin iPSCs
(Figure 3C). Among the 14 upregulated TFs, we selected
4 TFs, FOXD1, ID4, FOXO1, and CDX1, because their
GO terms were related to bones, mineralization, and oste-
oblast differentiation (Figure 3D). We also examined these
TF expressions in another Gorlin iPSC line (Gorlin 2)
derived from a different individual. FOXO1, FOXD1, and
ID4 were upregulated in both Gorlin-1 and Gorlin-2
iPSCs; however, CDX1 was not upregulated in Gorlin-2
iPSCs (Figure 3E).
We investigated the involvement of Hh signaling activa-
tion in the induction of these TFs in Gorlin iPSCs by treat-
ing them with or without GANT61, a direct inhibitor of
GLI1. Treatment with GANT61 resulted in neither increase
in GLI1 expression nor enhancement of calcification in
Gorlin iPSCs at day 17 of the osteoblast induction culture
(Figures 3F and 3G). Among the four TFs that we focused
on, GANT61 treatment significantly downregulated the ex-
pressions of FOXO1, FOXD1, and ID4 in Gorlin iPSCs, but
not inWT iPSCs, whereas CDX1 expression was not altered
by the treatment in either of the cell lines (Figure 3G),
which might reflect the difference in transcriptional net-
works between different types of PTCH1 mutations. Over-
all, these data suggest that FOXO1, FOXD1, and ID4 can
be targets of canonical Hh signaling (i.e., the Hh-Ptch-
Smo-Gli axis) andmay underlie the enhancement of osteo-
blastogenesis and calcification in Gorlin iPSCs. FOXO1 has
been reported to provide an intracellular environment
congenial to osteoblast differentiation (Kode et al., 2012;
Teixeira et al., 2010). CDX1 and FOXD1 take part in devel-
opment, malignant transformation, and ectopic bone for-
mation coordinately with WNT and BMPs (Regard et al.,
2013).
Comparison of Osteogenic Capacities between Gorlin
iPSCs and Their Isogenic Control iPSCs
To eliminate the influence of the different genetic back-
grounds of theWTand Gorlin iPSCs, we set out to generate
a reliable control iPSC clone for Gorlin-1 iPSCs, in which
themutation in exon 9 (c.1338-1341del CTCA; Figure S5A)
was corrected under the same genetic background, i.e., an
isogenic control. We utilized a Cas9 nickase-based
genome-editing technique in combinationwith a targeting
vector containing a 2-kb homology arm at the 50 side and a
1.7-kb homology arm at the 30 side (Figure S5B). We identi-
fied five clones showing correct insertion of the pgk-neo
cassette (Figure S5C) and selected one clone (clone 9), in
which the mutation in the PTCH1 gene was corrected to
the WT sequence, as an isogenic control for Gorlin-1 iPSCs
(Figure S5D). Themorphology of clone 9was indistinguish-
able from that of the original Gorlin-1 iPSCs (Figure S5E).
We then checked the WT and mutated PTCH1 mRNA
expression using locked nucleic acid-labeled probes in Gor-
lin-1 and isogenic control iPSCs. The expression pattern of
wild and mutated allele in isogenic control showed similar
to another type of control iPSC (WT3). The WT PTCH1
expression level was lower in Gorlin-1 iPSCs than in the
isogenic control, whereas the mutated PTCH1 level was
higher in Gorlin-1 iPSCs (Figure 4A). Gorlin-1 iPSCs
showed higher expression levels of GLI1 and HHIP than
the isogenic control (Figure 4B).
Figure 4. Comparison of Osteogenic Capacities between Gorlin iPSCs and Their Isogenic Control iPSCs in the Osteoblast Induction
Culture
(A) The mRNA expression of WT and mutated PTCH1 alleles under a serum starvation condition (DMEM supplemented with 0.5% fetal bovine
serum) in Gorlin-1, their isogenic control iPSCs, and WT3. qRT-PCR analysis was performed at day 2 of the culture. Data are the means ± SD
from three independent experiments. *p < 0.05.
(B) The mRNA expression of GLI1 and HHIP under the serum starvation condition in Gorlin-1 and their isogenic control iPSCs. qRT-PCR
analysis was performed at day 2 of the culture. Data are the means ± SD from three independent experiments. *p < 0.05.
(C) The mRNA expression of GLI1 and HHIP in the osteoblast induction culture of Gorlin-1 and their isogenic control iPSCs. qRT-PCR
analysis was performed at day 17 of the culture. Data are the means ± SD from three independent experiments. *p < 0.05. The normalized
expressions are shown relative to those of isogenic control iPSCs on day 17.
(D) Quantification of RUNX2-positive cells in the osteoblast induction culture of Gorlin-1 and their isogenic control iPSCs. FCM analysis was
performed for RUNX2 at days 10 and 17 of the culture. Blue dotted lines show signal intensities from the staining with the IgG isotype
control. Light blue and green lines show signal intensities from the staining with an anti-RUNX2 antibody.
(E) The mRNA expression of osteoblast marker genes in the osteoblast induction culture of Gorlin-1 and their isogenic control iPSCs. qRT-
PCR analysis was performed at the indicated days of the cultures. Data are the means ± SD from three independent experiments. *p < 0.05.
(F) Calcification in the osteoblast induction culture of Gorlin-1 and their isogenic control iPSCs. von Kossa staining was performed at day
17 of the culture.
(G) The mRNA expression of CDX1, FOXO1, ID4, and FOXD1 in the osteoblast induction culture of Gorin 1 and their isogenic control iPSCs.
qRT-PCR analysis was performed at day 17 of the culture. Data are the means ± SD from three independent experiments. *p < 0.05.
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We compared the osteogenic capacity between Gorlin
iPSCs and the isogenic control iPSCs in the osteoblast in-
duction culture. qRT-PCR analysis demonstrated that the
expressions of Hh signal-targeting genes, such as GLI1
and HHIP were significantly higher in Gorlin iPSCs than
in the isogenic control (Figure 4C). Fluorescence-activated
cell sorting analysis at days 10 and 17 showed more
RUNX2-positive cells among Gorlin iPSCs than among
the isogenic control cells (Figure 4D); expressions of the
osteogenic markers COL1A1, SP7, and BGLAP showed sig-
nificant upregulation only in Gorlin iPSCs at days 10 and
17 (Figure 4E). Gorlin iPSCs demonstrated more calcifica-
tion than the isogenic control cells at day 17 (Figure 4F).
We also compared the expression of the four TFs identified
by RNA-seq analysis (Figure 3) between Gorlin iPSCs and
the isogenic control iPSCs. All four factors, CDX1,
FOXO1, ID4, and FOXD1, were upregulated in Gorlin iPSCs
compared with the isogenic control cells (Figure 4G). Thus,
these findings were consistent with the data obtained from
the comparison between Gorlin iPSCs and the irrelevant
control iPSCs (Figures 1–3), supporting the positive impact
of the Gorlin syndrome-associated PTCH1mutation onHh
signaling activity and human osteoblastogenesis, and
providing clues to the possible mechanisms underlying
the impact.
Given that cyclopamine treatment did not completely
repress the mineralization in Gorlin iPSCs (Figure 2D),
the enhancedmineralization of Gorlin iPSCs cannot be ex-
plained by Hh signaling alone. The four TFs that we found
here may also be involved in the phenotype of Gorlin
iPSCs. We think that non-canonical Hh pathway and/or
other pathways, which are secondarily activated or in-
hibited, may underlie phenotypes caused by PTCH1
mutations.
Hh Signaling Activation Restores the Impaired
Osteoblast Formation in GNAS-Mutated iPSC-Derived
Osteoblasts
In addition to the osteogenic capacities, osteoblastogenesis
was prominently enhanced in Gorlin iPSCs. Two genetic
diseases associated with osteoblastogenesis, FD and the
related disease MAS, have been intensely studied.
We recently established an R201H-GNAS-mutated iPSC
line, N14 (MAS iPSC) by genetic manipulation using a
CRISPR/Cas9 system (T.A., S.O., K.W., A.S., T.S. and T.N.,
unpublished data). In this study, we set out to analyze the
calcification of the MAS iPSCs, in addition to Gorlin iPSCs,
to gain insight into the involvement of Hh signaling in the
mineralization following osteoblastogenesis.
In von Kossa staining, the level of calcification in MAS
iPSC-derived cells was much lower than that in control
parental iPSCs at day 17 of the osteoblast induction culture
(Figure 5A). Although some reports have described that
Wnt activation promotes osteoblastogenesis and minerali-
zation (Kato et al., 2002; Rodda andMcMahon, 2006),MAS
and FD are characterized by poor osteoblastogenesis with
immature mineralized bone with high Wnt activity and
low Hh activity (Khan et al., 2018). This suggests that
Figure 5. Hedgehog Activation Rescued a Calcification of GNAS-Mutated MAS iPSC-Derived Osteoblasts
(A) Calcification in the osteoblast induction culture of Gorlin-1 iPSCs, their isogenic control iPSCs, MAS iPSCs (N14), and their parental
cells (WT3) with or without SAG treatment. von Kossa staining was performed at days 0 and 17 of the osteoblast induction culture. Mineral
deposition was detected as black staining.
(B) The mRNA expression of BGLAP in the osteoblast induction culture of Gorlin-1 iPSCs, their isogenic control iPSCs, MAS iPSCs (N14), and
their parental cells (WT3). qRT-PCR analysis was performed at day 17 of the culture. Data are the means ± SD from three independent
experiments. *p < 0.05.
(C) The mRNA expression of AXIN2 and TCF7 in the osteoblast induction culture of Gorlin-1 iPSCs, their isogenic control iPSCs, MAS iPSCs
(N14), and their parental cells (WT3). qRT-PCR analysis was performed at day 17 of the culture. Data are the means ± SD from three
independent experiments. *p < 0.05.
(D) The mRNA expression of HHIP in the osteoblast induction culture of Gorlin-1 iPSCs, their isogenic control iPSCs, MAS iPSCs (N14), and
their parental cells (WT3). qRT-PCR analysis was performed at day 17 of the culture. Data are the means ± SD from three independent
experiments. *p < 0.05.
(E) The mRNA expression of HHIP in the osteoblast induction culture treated with or without SAG of MAS iPSCs (N14) and their parental
cells (WT3). qRT-PCR analysis was performed at day 17 of the culture. Data are the means ± SD from three independent experiments. *p <
0.05.
(F) The mRNA expression of AXIN2 and TCF7 in the osteoblast induction culture treated with or without SAG of MAS iPSCs (N14) and their
parental cells (WT3). qRT-PCR analysis was performed at day 17 of the culture. Data are the means ± SD from three independent exper-
iments. *p < 0.05.
(G) The mRNA expression of CDX1, FOXO1, ID4, and FOXD1 in the osteoblast induction culture of Gorlin-1 iPSCs, their isogenic control iPSCs,
MAS iPSCs (N14), and their parental cells (WT3). qRT-PCR analysis was performed at day 17 of the culture. Data are the means ± SD from
three independent experiments. *p < 0.05.
(H) Schematic illustration of possible molecular mechanisms underlying phenotypes of osteoblasts derived from MAS iPSCs (top), MAS
iPSCs with Hh activators (middle), and Gorlin iPSCs (bottom).
Stem Cell Reports j Vol. 15 j 125–139 j July 14, 2020 135
Wnt activation does not always correlate with high osteo-
blastogenesis and mineralization. Rather, we hypothesized
that the low Hh signaling activity might be responsible for
the poor osteoblastogenesis and immature bone pheno-
type of MAS or FD. To test this hypothesis, we treated
MAS iPSCs with the SAG to upregulate Hh signaling; SAG
treatment enhanced mineralization to the same extent
not only in the parental cells, but also inMAS iPSC-derived
cells (Figure 5A), supporting the above hypothesis. MAS
iPSC-derived cells showed a poor response to the osteo-
genic induction compared with Gorlin iPSCs, as shown
by the expression of BGLAP (Figure 5B). Regarding the
mechanistic aspects of the differential response, MAS
iPSC-derived cells showed significant upregulation of the
canonical Wnt signaling target genes AXIN2 and TCF7
compared with the parental cells in the induction culture,
which was consistent with previous findings (Xu et al.,
2018), whereas the Gorlin iPSC-derived cells did not (Fig-
ure 5C). In contrast, HHIP, an Hh signaling target gene,
was upregulated in Gorlin iPSC-derived cells, not in MAS
iPSC-derived ones (Figure 5D). The SAG treatment, which
restored mineralization, upregulated HHIP and downregu-
lated AXIN2 and TCF7 in MAS iPSC-derived cells (Figures
5E and 5F), suggesting that changes in both Hh and Wnt
signaling activities underlie the effect of SAG on
osteoblastogenesis.
Next, we investigated the expression levels of the four
TFs (CDX1, FOXO1, ID4, and FOXD1) that we found in
the earlier experiments, to examine whether any common
factors acting downstream of Hh signaling underlay the
opposite phenotypes of mineralization in Gorlin iPSCs
and MAS iPSCs. CDX1, ID4, and FOXD1, but not FOXO1,
were upregulated in MAS iPSC-derived osteoblasts (Fig-
ure 5G); the absence of upregulation of FOXO1 may be
consistent with lowHh activity caused by GNAS activation
in MAS iPSCs, suggesting that FOXO1, the expression of
which may be regulated by Hh signaling activity,
commonly underlies the mineralization phenotypes
following osteoblastogenesis of MAS iPSCs and Gorlin
iPSCs.
DISCUSSION
Hh signaling is a vital pathway for formation and mainte-
nance of bone tissues. Disruption of Hh signaling virtually
disables osteo-chondral tissue formation (Long et al.,
2004). In human, PTHC1 mutations cause constitutive
Hh signaling activation and give rise to Gorlin syndrome
characterized by neoplastic lesions and skeletal abnormal-
ities (Gorlin, 1995; Gorlin and Goltz, 1960). Gorlin syn-
drome patients often have hyper-mineralization of bones.
In contrast, FD, which has constitutive activation of
GNASwithGNAS genemutation (GNAS R201H), often pre-
sents poor mineralization. This GNAS mutation is also
known as a causative mutation of MAS. We generated
two of these genetic disease-specific hiPSCs and attempted
to elucidate the central roles of Hh in bone pathophysi-
ology. Here, we present three major findings (Figure 5H).
First, Gorlin iPSCs showed enhanced mineralization with
upregulation of Hh activity and specific TFs (full-length
GLI3 and FOXO1). Second,MAS iPSCs showed poorminer-
alization with reduced Hh activity and no upregulation of
FOXO1 expression; distinctive TFs acting downstream of
Hh signaling, particularly FOXO1, may commonly under-
lie the phenotypes of the two diseases. Third, Hh activator
SAG treatment normalized premature calcification in MAS
iPSCs. These data suggest that Hh signalingmay play a cen-
tral role in osteoblast formation and subsequent bone
mineralization, and Hh activator SAG can be an effective
therapeutic agent for FD found in solitary FD or MAS.
We found that regulations of GLI3 processing from
GLI3FL to GLI3rep mediate the biological outcome of Hh
signaling in osteoblasts. The biological function of GLI3
processing has been intensively discussed in mouse limb
digit patterning. The ratio of GLI3FL to GLI3rep or their
gradient balance was proposed to determine the Shh-
mediated numbers and specifications of limb (Wang
et al., 2000; Wang et al., 2007; Litingtung et al., 2002).
Our data showed that GLI3FL, activator of Hh pathway,
was dominant and might further have enhanced Gorlin
iPSCs osteoblast differentiation.
A number of studies have shown that the Hh and Wnt
signaling pathways are functionally antagonistic (He
et al., 2006; Katoh and Katoh, 2006; Xu et al., 1998). Wnt
activation was reported to upregulate Gli3, a transcrip-
tional repressor, which in turn suppresses Hh signaling (Al-
varez-Medina et al., 2008). In addition, GNAS activates pro-
tein kinase A (PKA), and PKA activation promotes GLI3
processing to increase GLI3rep (Orellana and McKnight,
1992; Wen et al., 2010). Based on these findings, we pro-
pose the following mechanism to explain the impaired
calcification in MAS iPSC-derived osteoblastic cells. The
cells with constitutively activated GNAS may have more
GLI3 expression due to the activation of Wnt signaling;
the increased GLI3 may be progressively processed into
GLI3rep by GNAS-mediated PKA activation, causing low
Hh signaling activity.
Our results also suggest that FOXO1 expression may un-
derlie the functional relationship between Hh and Wnt
signaling. Mouse models have highlighted profound influ-
ences of FoxOs on bone development. Among the four iso-
forms, FoxO1 is highly expressed in the skeleton and is also
known as amajor regulator of osteoblast function and bone
metabolism (Ambrogini et al., 2010). FoxO1, 3, and 4 dele-
tion using the Mx1-cre driver line (Ambrogini et al., 2010)
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and FoxO1 deletion using the Col1a1-Cre driver line
(Rached et al., 2010) caused osteoporotic phenotypes in
mice. FoxOs promoted maintenance and differentiation
of the progenitors into the osteoblast lineage by activation
of Runx2 (Ambrogini et al., 2010; Rached et al., 2010).
Consistent with these studies, bone volume and bone for-
mation rate were decreased in Bglap-Cre-driven FoxO1-defi-
cientmice, whichwere related to a decreased number of os-
teoblasts (Zhang et al., 2018). On the other hand, FoxO1, 3,
and 4 deletion in Osterix1 (Sp7)-expressing osteoblast pro-
genitors led to high bone mass phenotypes accompanied
with increased proliferation of the progenitors in mice;
activation of Wnt/b-catenin signaling was observed in
the mutants’ progenitors (Iyer et al., 2013). These results
suggest that FOXOs have diverse functions at different
stages of osteoblast differentiation. In addition, amolecular
link between FOXOs and Wnt/b-catenin signaling is also
reported in colon cancer cell models, in which FOXOs
divert b-catenin from TCF- to FOXO-mediated transcrip-
tion (Hoogeboom et al., 2008).
Previous studies have revealed an association between
the activation of canonical Wnt signaling in osteoblasts
and increased bone formation (Day and Yang, 2008). It
has been reported that deletion of the murineWnt antago-
nist, secreted frizzled-related protein 1, increased the
trabecular bone mineral density, volume, and mineral
apposition rate due to Wnt activation (Bodine et al.,
2004). In contrast, our present study and previous reports
showed that constitutive activation of GNAS resulted in
poor mineralization despite high Wnt activity, indicating
that Wnt activation alone is not sufficient for mineraliza-
tion. Our results further support the idea that activation
of Hh signaling at an early stage of osteogenesis is indis-
pensable for subsequent osteoblast maturation and miner-
alization, and insufficient Hh signaling is likely to be a ma-
jor cause of the poor bone maturation of FD observed in
MAS. The present results also highlight Hh signaling as a
potential therapeutic target to promote maturation of
MAS osteoblasts (Figure 5H). Thus, this study is an impor-
tant first step in the consideration of Hh activators as ther-
apeutic agents for the treatment of FD. Our approach may
help not only to investigate the pathogenesis ofGorlin syn-
drome and MAS, but also to understand the molecular
mechanisms underlying tissue development and homeo-
stasis, including the essential roles played by Hh in osteo-
blast maturation and mineralization.
EXPERIMENTAL PROCEDURES
Ethics
This studywas approved by the ethics committees of TokyoDental
College (approval no. 533) and the University of Tokyo (approval
no. 15-3). Written informed consent was obtained from patients
whose cells were isolated and subjected to reprogramming for
this study. Data were analyzed anonymously in accordance with
the Declaration of Helsinki.
Osteoblast Differentiation
Osteoblast differentiationofhiPSCswasperformedasdescribedpre-
viously,withminormodifications (Kankeet al., 2014).B27+ ITSme-
dium was used as the basal medium during the differentiation and
was supplemented with small molecules for each step. The B27 +
ITS medium consisted of DMEM/F12 (no. 11330-032; Gibco) con-
taining13MEMnon-essential aminoacids (no. 11140-050;Gibco),
13 B-27 serum-free supplement (no. 17504-044; Gibco), 13 ITS + 1
liquidmedia supplement (no. I2521; Sigma-Aldrich, St. Louis,MO),
0.1mM2-mercaptoethanol (no. 21985-023; Gibco), and penicillin/
streptomycin (no. P4458; Sigma-Aldrich). After washing the cells
with PBS, the 3-day induction protocolwas initiated to differentiate
the cells toward a mesoderm lineage. In the induction, cells were
cultured on vitronectin-coated dishes in B27 + ITSmedium supple-
mented with 20 mM CHIR99021 (no. 4423; Tocris Bioscience, Bris-
tol, UK) and 5 mM cyclopamine (no. C9710; LKT Laboratories, St.
Paul, MN). To induce osteoblast differentiation, we then cultured
thehiPSC-derivedmesodermal cells for 14days inB27+ ITSmedium
supplemented with 50 mg/mL ascorbic acid phosphate (no. A4034;
Sigma-Aldrich), 10 mM b-glycerophosphate (no. G9422; Sigma-Al-
drich), 0.1 mM dexamethasone (no. 041–18861; Wako, Osaka,
Japan), and 1 mMof the helioxanthin derivative TH (4-(4-methoxy-
phenyl)pyrido[40,30:4,5]thieno[2,3-b]pyridine-2-carboxamide; syn-
thesized by Tokyo Chemical Industry, Tokyo), in the presence or
absence of 1 mMSAG (no. 566660;MerckMillipore,Darmstadt,Ger-
many). The culturemediumwas replaceddaily. For the inhibitionof
Hh signaling, 0.5 mM cyclopamine was added to the medium.
Statistical Analysis
All data are expressed as the mean ± SD. When ANOVA indicated
differences among the groups, multiple comparisons among
each experimental group were performed using Bonferroni’s
method. Statistical significance was defined at p < 0.05.
DATA AND CODE AVAILABILITY
The RNA-seq data obtained in this work are available at the Na-
tional Bioscience Database Center (NBDC) hum 0107
(JGAS00000000218).
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2020.05.008.
AUTHOR CONTRIBUTIONS
S.Onodera, T.A., and S.Ohba designed the project. S.Onodera,
D.H., N.M., K.W., and D.Z. performed the experiments. D.H.,
N.M., T.N., and T.S. collected data and samples from each patient.
S.Onodera., T.A., A.S., T.N., A.Y., U.C., H.H., and S.Ohba analyzed
and interpreted the data. S.Onodera, T.A., and S.Ohba wrote the
manuscript. T.A. and S.Ohba supervised the project and approved
the final version of the manuscript.
Stem Cell Reports j Vol. 15 j 125–139 j July 14, 2020 137
ACKNOWLEDGMENTS
We thank Drs. Mahito Nakanishi (National Institute of Advanced
Industrial Science and Technology ‒AIST), Manami Ohtaka
(AIST), and Ken Nishimura (University of Tsukuba) for providing
technical assistance. This work utilized the core research facility
of the Center for Disease Biology and Integrative Medicine, The
University of Tokyo, which was organized by The University of To-
kyo Center for NanoBio Integration entrusted by the Ministry of
Education,Culture, Sports, Science and Technology (MEXT) Japan.
This work was supported by a JSPS KAKENHI grant (no.
JP17H04403, no. JP16K20427, and no. JP18H03007); a Rising
Star Award Grant from the American Society for Bone andMineral
Research (to S.Ohba); Tokyo Dental College Research Branding
Project; the JSPS Graduate Program for Leaders in Life Innovation
(GPLLI); the JSPS Core-to-Core Program (Advanced Research Net-
works); and the Japan Science and Technology Agency (JST) Center
of Innovation Program (COI).
Received: January 23, 2020
Revised: May 12, 2020
Accepted: May 13, 2020
Published: June 11, 2020
REFERENCES
Albright, F., Butler, A.M., Hampton, A.O., Smith, P., Butler, A.,
Hampton, A., Smith, P., Mastorakos, G., Mitsiades, N., Doufas,
A., et al. (1937). Syndrome characterized by osteitis fibrosa dissem-
inata, areas of pigmentation and endocrine dysfunction, with pre-
cocious puberty in females. N. Engl. J. Med. 216, 727–746.
Alman, B.A. (2015). The role of hedgehog signalling in skeletal
health and disease. Nat. Rev. Rheumatol. 11, 552–560.
Alvarez-Medina, R., Cayuso, J., Okubo, T., Takada, S., and Martı́, E.
(2008). Wnt canonical pathway restricts graded Shh/Gli
patterning activity through the regulation of Gli3 expression.
Development 135, 237–247.
Ambrogini, E., Almeida, M., Martin-Millan, M., Paik, J.H., De-
Pinho, R.A., Han, L., Goellner, J., Weinstein, R.S., Jilka, R.L.,
O’Brien, C.A., et al. (2010). FoxO-mediated defense against oxida-
tive stress in osteoblasts is indispensable for skeletal homeostasis in
mice. Cell Metab. 11, 136–146.
Bodine, P.V.N., Zhao, W., Kharode, Y.P., Bex, F.J., Lambert, A.-J.,
Goad, M.B., Gaur, T., Stein, G.S., Lian, J.B., and Komm, B.S.
(2004). The Wnt antagonist secreted frizzled-related protein-1 is
a negative regulator of trabecular bone formation in adult mice.
Mol. Endocrinol. 18, 1222–1237.
Briscoe, J., and Thérond, P.P. (2013). Themechanisms of Hedgehog
signalling and its roles in development and disease. Nat. Rev. Mol.
Cell Biol. 14, 416–429.
Day, T.F., and Yang, Y. (2008). Wnt and hedgehog signaling path-
ways in bone development. J. Bone Joint Surg. Am. 90, 19–24.
Fujii, K., and Miyashita, T. (2014). Gorlin syndrome (nevoid basal
cell carcinoma syndrome): update and literature review. Pediatr.
Int. 56, 667–674.
Goodrich, L.V., Milenkovic, L., Higgins, K.M., and Scott, M.P.
(1997). Altered neural cell fates and medulloblastoma in mouse
patched mutants. Science 277, 1109–1113.
Gorlin, R.J. (1995). Nevoid basal cell carcinoma syndrome. Derma-
tol. Clin. 13, 113–125.
Gorlin, R.J., and Goltz, R.W. (1960). Multiple nevoid basal-cell
epithelioma, jaw cysts and bifid rib. A syndrome. N. Engl. J. Med.
262, 908–912.
Hasegawa, D., Ochiai-Shino, H., Onodera, S., Nakamura, T., Saito,
A., Onda, T., Watanabe, K., Nishimura, K., Ohtaka, M., Nakanishi,
M., et al. (2017). Gorlin syndrome-derived induced pluripotent
stem cells are hypersensitive to hedgehog-mediated osteogenic in-
duction. PLoS One 12, e0186879.
He, J., Sheng, T., Stelter, A.A., Li, C., Zhang, X., Sinha, M., Luxon,
B.A., and Xie, J. (2006). Suppressing Wnt signaling by the hedge-
hog pathway through sFRP-1. J. Biol. Chem. 281, 35598–35602.
Hoogeboom, D., Essers, M.A.G., Polderman, P.E., Voets, E., Smits,
L.M.M., and Burgering, B.M.T. (2008). Interaction of FOXO with
b-catenin inhibits b-catenin/T cell factor activity. J. Biol. Chem.
283, 9224–9230.
Ingham, P.W., and McMahon, A.P. (2001). Hedgehog signaling in
animal development: paradigms and principles. Genes Dev. 15,
3059–3087.
Iyer, S., Ambrogini, E., Bartell, S.M., Han, L., Roberson, P.K., De
Cabo, R., Jilka, R.L., Weinstein, R.S., O’Brien, C.A., Manolagas,
S.C., et al. (2013). FOXOs attenuate bone formation by suppressing
Wnt signaling. J. Clin. Invest. 123, 3409–3419.
Joeng, K.S., and Long, F. (2009). The Gli2 transcriptional activator
is a crucial effector for Ihh signaling in osteoblast development and
cartilage vascularization. Development 136, 4177–4185.
Kanke, K., Masaki, H., Saito, T., Komiyama, Y., Hojo, H., Nakauchi,
H., Lichtler, A.C., Takato, T., Chung, U.-I., and Ohba, S. (2014).
Stepwise differentiation of pluripotent stem cells into osteoblasts
using four small molecules under serum-free and feeder-free condi-
tions. Stem Cell Reports 2, 751–760.
Kato, M., Patel, M.S., Levasseur, R., Lobov, I., Chang, B.H.-J., Glass,
D.A., Hartmann, C., Li, L., Hwang, T.-H., Brayton, C.F., et al.
(2002).Cbfa1-independent decrease in osteoblast proliferation, os-
teopenia, and persistent embryonic eye vascularization in mice
deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 157, 303–314.
Katoh, Y., and Katoh,M. (2006).WNTantagonist, SFRP1, is Hedge-
hog signaling target. Int. J. Mol. Med. 17, 171–175.
Khan, S.K., Yadav, P.S., Elliott, G., Hu, D.Z., Xu, R., and Yang, Y.
(2018). Induced GnasR201H expression from the endogenous
Gnas locus causes fibrous dysplasia by up-regulating Wnt/b-cate-
nin signaling. Proc. Natl. Acad. Sci. U S A 115, E418–E427.
Kode, A.,Mosialou, I., Silva, B.C., Rached,M.-T., Zhou, B.,Wang, J.,
Townes, T.M., Hen, R., DePinho, R.A., Guo, X.E., et al. (2012).
FOXO1 orchestrates the bone-suppressing function of gut-derived
serotonin. J. Clin. Invest. 122, 3490–3503.
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Degu-
chi, K., Shimizu, Y., Bronson, R.T., Gao, Y.H., Inada, M., et al.
(1997). Targeted disruption of Cbfa1 results in a complete lack of
bone formation owing to maturational arrest of osteoblasts. Cell
89, 755–764.
138 Stem Cell Reports j Vol. 15 j 125–139 j July 14, 2020
Lichtenstein, L. (1938). Polyostotic fibrous dysplasia. Arch. Surg.
36, 874.
Litingtung, Y., Dahn, R.D., Li, Y., Fallon, J.F., andChiang, C. (2002).
Shh andGli3 are dispensable for limb skeleton formation but regu-
late digit number and identity. Nature 418, 979–983.
Long, F., Chung, U., Ohba, S., McMahon, J., Kronenberg, H.M.,
and McMahon, A.P. (2004). Ihh signaling is directly required for
the osteoblast lineage in the endochondral skeleton. Development
131, 1309–1318.
Mullor, J.L., Sánchez, P., and Ruiz i Altaba, A. (2002). Pathways and
consequences: hedgehog signaling in human disease. Trends Cell
Biol 12, 562–569.
Ohba, S., Nakajima, K., Komiyama, Y., Kugimiya, F., Igawa, K.,
Itaka, K., Moro, T., Nakamura, K., Kawaguchi, H., Takato, T., et al.
(2007). A novel osteogenic helioxanthin-derivative acts in a
BMP-dependent manner. Biochem. Biophys. Res. Commun. 357,
854–860.
Ohba, S., Kawaguchi, H., Kugimiya, F., Ogasawara, T., Kawamura,
N., Saito, T., Ikeda, T., Fujii, K., Miyajima, T., Kuramochi, A., et al.
(2008). Patched1 haploinsufficiency increases adult bone mass
and modulates Gli3 repressor activity. Dev. Cell 14, 689–699.
Orellana, S.A., and McKnight, G.S. (1992). Mutations in the cata-
lytic subunit of cAMP-dependent protein kinase result in unregu-
lated biological activity. Proc. Natl. Acad. Sci. U S A 89, 4726–4730.
Rached, M.-T., Kode, A., Xu, L., Yoshikawa, Y., Paik, J.-H., DePinho,
R.A., and Kousteni, S. (2010). FoxO1 is a positive regulator of bone
formation by favoring protein synthesis and resistance to oxida-
tive stress in osteoblasts. Cell Metab. 11, 147–160.
Regard, J.B., Malhotra, D., Gvozdenovic-Jeremic, J., Josey, M.,
Chen, M., Weinstein, L.S., Lu, J., Shore, E.M., Kaplan, F.S., and
Yang, Y. (2013). Activation of Hedgehog signaling by loss of
GNAS causes heterotopic ossification. Nat. Med. 19, 1505–1512.
Rodda, S.J., andMcMahon, A.P. (2006). Distinct roles for Hedgehog
and canonical Wnt signaling in specification, differentiation and
maintenance of osteoblast progenitors. Development 133, 3231–
3244.
St-Jacques, B., Hammerschmidt, M., and McMahon, A.P. (1999).
Indian hedgehog signaling regulates proliferation and differentia-
tion of chondrocytes and is essential for bone formation. Genes
Dev. 13, 2072–2086.
Teixeira, C.C., Liu, Y., Thant, L.M., Pang, J., Palmer, G., and Ali-
khani, M. (2010). Foxo1, a novel regulator of osteoblast differenti-
ation and skeletogenesis. J. Biol. Chem. 285, 31055–31065.
Turan, S., and Bastepe, M. (2015). GNAS spectrum of disorders.
Curr. Osteoporos. Rep. 13, 146–158.
Wang, B., Fallon, J.F., and Beachy, P.A. (2000). Hedgehog-regulated
processing of Gli3 produces an anterior/posterior repressor
gradient in the developing vertebrate limb. Cell 100, 423–434.
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